{"id":227513,"title":"Policy Statement: Clarifying the appropriate regulatory pathway for subsequent entry low molecular weight heparins - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-19","captureTimestamp":"2025-04-19T05:29:19.014000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/policy-statement-clarifying-appropriate-regulatory-molecular-weight-heparins.html?wbdisable=true","snippet":"Policy Statement: Clarifying the appropriate regulatory pathway for subsequent entry low molecular weight heparins - Canada.ca Skip to main content Skip to \"About government\" Skip to section menu Language selection Français fr / Gouvernement du Canada Search Search Canada.ca…","rawSnapshotUrl":"/api/snapshots/raw/227513","browseUrl":"https://replay.healtharchive.ca/job-1/20250419052919/https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/policy-statement-clarifying-appropriate-regulatory-molecular-weight-heparins.html?wbdisable=true#ha_snapshot=227513","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}